Distinguishing Invasive from Chronic Pulmonary Infections: Host Pentraxin 3 and Fungal Siderophores in Bronchoalveolar Lavage Fluids.
Radim Dobiáš, Pavla Jaworská, Valeria Skopelidou...
https://pubmed.ncbi.nlm.nih.gov/36422015/Actively Recruiting
Led by University Hospital Ostrava · Updated on 2023-09-07
150
Participants Needed
7
Research Sites
52 weeks
Total Duration
Researchers are investigating invasive pulmonary aspergillosis IPA, a serious lung infection mostly caused by Aspergillus fumigatus, which has increased significantly in critically ill patients, especially those with severe respiratory infections like COVID-19 and H1N1. Current biomarkers only suggest probable IPA, so this study aims to evaluate new low molecular weight substances combined with acute-phase proteins to confirm IPA quickly and accurately. The goal is to improve early diagnosis and treatment outcomes in intensive care patients. This study collects multiple types of samples such as tissue, bronchoalveolar lavage fluid, endotracheal aspirate, breath condensate, serum, and urine from patients suspected of IPA. Using advanced mass spectrometry techniques including MALDI-TOF, researchers will detect specific microbial markers alongside host proteins to confirm infection. Samples will be taken twice weekly until negative results or discharge, and stored samples from before diagnosis may also be analyzed. The study compares groups of patients with suspected IPA and those with probable or proven IPA. Participants will undergo regular testing including imaging, mycological cultures, PCR tests, and biomarker analyses. Data on clinical history, treatment, and biological markers will be collected and analyzed statistically to evaluate the diagnostic accuracy of the new methods. Results will be reported to clinicians in variable timeframes. The primary outcome is the concentration of IPA markers detected by mass spectrometry over 31 months. The study runs until the end of 2026 and involves critically ill adult patients in intensive care units.
CONDITIONS
Early Diagnosis of Invasive Lung Aspergillosis
J
Jiří Hynčica
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital Ostrava
Lead Sponsor
Public Health Institute Ostrava
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From diagnosis until at least 2 consecutive negative results are obtained or discharge from intensive care
Participants with suspected invasive pulmonary aspergillosis (IPA) undergo collection of samples twice a week for analysis, including tests such as galactomannan screening, PTX3, Aspergillus qPCR, and mass spectrometry. Stored samples taken prior to diagnosis may also be analyzed to aid early detection.
Twice weekly sample collections
Duration - 6 months
Participants are classified at 6 months after diagnosis as having possible, probable, or proven IPA. Clinical and biological data, including imaging and treatment outcomes, are collected to monitor disease progression and response.
Follow-up assessments as determined by clinical care
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Radim Dobiáš, Pavla Jaworská, Valeria Skopelidou...
https://pubmed.ncbi.nlm.nih.gov/36422015/Catia Cillóniz, Antoni Torres, Michael S Niederman
https://pubmed.ncbi.nlm.nih.gov/34872910/C Oliver Morton, P Lewis White, Rosemary A Barnes...
https://pubmed.ncbi.nlm.nih.gov/28339744/Wouter Meersseman, Katrien Lagrou, Johan Maertens...
https://pubmed.ncbi.nlm.nih.gov/17885264/Thomas Lehrnbecher, Angela Hassler, Andreas H Groll...
https://pubmed.ncbi.nlm.nih.gov/29632518/Azmi Khan, Pratika Singh, Amrita Srivastava
https://pubmed.ncbi.nlm.nih.gov/29103733/Ben De Pauw, Thomas J Walsh, J Peter Donnelly...
https://pubmed.ncbi.nlm.nih.gov/18462102/Jan Springer, Jürgen Held, Carlo Mengoli...
https://pubmed.ncbi.nlm.nih.gov/33810069/Philipp Koehler, Matteo Bassetti, Arunaloke Chakrabarti...
https://pubmed.ncbi.nlm.nih.gov/33333012/G Marshall Lyon, Deborah Abdul-Ali, Juergen Loeffler...
https://pubmed.ncbi.nlm.nih.gov/23616459/University Hospital Ostrava
Lead Sponsor
Public Health Institute Ostrava
Collaborating Sponsor